IRulya Therapeutics Inc.

IRulya Therapeutics Inc. (CRTX) priced its initial public offering on May 9, 2019 at $17.00 per share, within its $16.00–$18.00 range, raising $75M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $442.2M. Credit Suisse was lead-left underwriter, joined by Canaccord Genuity and Citizens JMP. Orrick advised the company and Latham & Watkins advised the underwriters.

At its 2019 IPO, Cortexyme, Inc. (now IRulya Therapeutics) was a clinical-stage biopharmaceutical company developing COR388, which targets P. gingivalis and its toxic gingipain proteases, proposed as an underlying cause of Alzheimer's disease and other degenerative diseases.

Status

IPO

Ticker

CRTX

Exchange

Nasdaq Global Select

Priced

May 9, 2019

IPO price

$17.00

Price range

$16.00–$18.00

Raised

$75M

Market cap at IPO price

$442.2M

First filed

Apr 12, 2019

Underwriters

Credit Suisse, Canaccord Genuity and Citizens JMP

Company counsel

Orrick

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

CT

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.